September 25th 2024
A continuous increase in ASCVD risk was seen with higher levels of lipoprotein(a) in the largest study to date of the relationship.
Diabetes: How Early--and Aggressively--to Intervene
November 1st 2005The growing epidemic of type 2 diabetes makes it imperative to identify persons at risk, screen for impaired glucose tolerance (IGT), and treat to prevent progression. Calculation of body mass index (BMI) is an appropriate starting point for identification of patients with possible IGT.
Evidence-Based Cardiovascular Disease Prevention: Challenges to Assessing Risk in Office Practice
November 1st 2005Cardiovascular (CV) risk-reduction regimens require comprehensive assessment, patient education, and follow-up, which can be difficult and time-consuming in a busy primary care practice. Moreover, compliance among patients at high risk can be poor. The use of evidence- based risk assessment checklists and patient education materials can enhance care and improve compliance; in addition, thorough documentation can ensure full reimbursement for services.
Statin-Drug Interactions: Update on the Most Common and Clinically Significant
September 15th 2005Statins (HMG-CoA reductase inhibitors) are the most effective drugs in the management of elevated low-density lipoprotein cholesterol (LDL-C) levels. Recent large clinical trials continue to demonstrate the remarkable efficacy of these agents, including improved outcomes.
The Metabolic Syndrome: Early Clues, Effective Management
September 15th 2005The metabolic syndrome represents a clustering of conditions and/or risk factors that lead to an increased incidence of type 2 diabetes mellitus and cardiovascular disease. These conditions include abdominal obesity, dyslipidemia, hypertension, insulin resistance, and a proinflammatory state.
Jumping to Conclusions About Appendicitis
September 14th 2005A male infant was born to a 29-year-old woman (gravida 3, para 2), following an uncomplicated pregnancy and normal vaginal delivery. At birth, a brownish 1-cm nodule was noted on the right side of the upper abdomen. The infant was otherwise healthy.
Lower Is Better Redux: What TNT Tells Us About Aggressive Lipid Lowering
September 1st 2005For years, cardiologists and primary care physicians have engaged in a spirited debate about the appropriate target for low-density lipoprotein cholesterol (LDL-C) lowering in patients with coronary artery disease.
Clinical Update: C-reactive protein: A marker for assessing and managing cardiac risk
July 1st 2005Inflammation plays a major role in coronary artery disease (CAD), whereby inflammatory changes develop in the blood vessel walls.1 This observation has spurred interest in exploring the connection between CAD and markers of inflammation, including C-reactive protein (CRP), fibrinogen, serum amyloid A, and many other novel markers.
Acanthosis Nigricans in an Adolescent With Metabolic Syndrome
July 1st 2005During a routine annual checkup, a 5-ft 8-in, 94.5-kg (210-lb) 13-year-old girl was noted to have a hyperpigmented "dirty" lesion on the back of her neck. The girl's parents were also obese. Her mother had type 2 diabetes mellitus.
High LDL and HDL: Implications in a Perimenopausal Woman
June 1st 2005I would like to offer a few comments on the reply by Dr Michael Prisant to a reader's question about whether statin therapy is appropriate for a 52-year-old woman with a high low-density lipoprotein (LDL) cholesterol level and a high high-density lipoprotein (HDL) cholesterol level
How to Manage Insulin Resistance in Children
May 1st 2005As recommended by the authors, I commonly order a fasting lipid profile and measurements of glucose and insulin levels in children at risk for type 2 diabetes. One area of management that remains confusing is the approach to take with children who have an elevated fasting insulin level but otherwise normal laboratory results.